Get the Stockscreener App
0.6127
3.21%
-0.0203
After Hours:
.60
-0.0127
-2.07%
Hoth Therapeutics Inc stock is traded at $0.6127, with a volume of 222.32K.
It is down -3.21% in the last 24 hours and down -16.07% over the past month.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA). Its current assets are focused in treating cancer, skin toxicities, Alzheimer's, and weight loss.
See More
Previous Close:
$0.633
Open:
$0.611
24h Volume:
222.32K
Relative Volume:
0.11
Market Cap:
$11.72M
Revenue:
-
Net Income/Loss:
$-12.47M
P/E Ratio:
-0.6725
EPS:
-0.9111
Net Cash Flow:
$-10.10M
1W Performance:
-7.18%
1M Performance:
-16.07%
6M Performance:
-48.08%
1Y Performance:
-28.77%
1-Day Range:
$0.6012
$0.6298
1-Week Range:
$0.6012
$0.6999
52-Week Range:
$0.4894
$2.115
Hoth Therapeutics Inc Stock (HOTH) Company Profile
Name
Hoth Therapeutics Inc
Sector
Industry
Phone
(646)756-2997
Address
720 MONROE STREET, HOBOKEN, NY
Compare HOTH vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOTH
Hoth Therapeutics Inc
|
0.6127 | 12.11M | 0 | -12.47M | -10.10M | -0.9111 |
VRTX
Vertex Pharmaceuticals Inc
|
436.58 | 110.90B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
629.68 | 73.20B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
776.26 | 49.71B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.27 | 38.32B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
144.37 | 30.97B | 742.00K | -1.37B | -1.07B | -7.0731 |
Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-19 | Initiated | The Benchmark Company | Speculative Buy |
Hoth Therapeutics Inc Stock (HOTH) Latest News
HOTH Should I Buy - Intellectia AI
Hoth Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Hoth Therapeutics (NASDAQ: HOTH) Q1 loss deepens going-concern risk despite new funding - Stock Titan
HOTH.O - Reuters
TradingKey - TradingKey
Hoth Therapeutics stock (US44133K1097): Spain greenlights Phase 2a trial for HT-001 in cancer skin t - AD HOC NEWS
HOTH.O Technical Analysis & Stock Price Forecast - Intellectia AI
Hoth Therapeutics Launches Rocket One Space Subsidiary Initiative - TipRanks
Hoth Therapeutics (NASDAQ: HOTH) creates Rocket One for space assets - Stock Titan
Hoth Therapeutics Receives Nasdaq Minimum Bid Price Deficiency Notice - The Globe and Mail
Hoth Therapeutics secures European authorization in Spain - marketscreener.com
Hoth Therapeutics Secures European Authorization In Spain - TradingView
Hoth Therapeutics secures Spain approval for phase 2a trial - Investing.com
Hoth Therapeutics secures Spain approval for phase 2a trial By Investing.com - Investing.com Australia
Hoth Therapeutics Secures European Authorization in Spain for HT-001 Phase 2a Trial as Interim Data Show Strong Efficacy in Cancer Patients - The AI Journal
Cancer patients stayed on treatment as Hoth trial eased rash - Stock Titan
Hoth Therapeutics Receives Nasdaq Delisting Notice for Non-Compliance With Minimum Bid Price Rule - Minichart
Hoth Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Hoth Therapeutics (HOTH) faces Nasdaq $1 bid-price deficiency and delisting risk - Stock Titan
Why is HOTH stock up 70% after-hours today? - MSN
Exclusive: Hoth Therapeutics targets faster drug discovery with new AI platform - MSN
HOTH Technical Analysis | Trend, Signals & Chart Patterns | HOTH THERAPEUTICS INC (NASDAQ:HOTH) - ChartMill
HOTH Hoth Therapeutics Inc. posts wider than expected Q4 2025 loss even as shares climb nearly 8 percent in today's trading.Decline Risk - Cổng thông tin điện tử tỉnh Tây Ninh
Hoth Therapeutics, Inc.Common Stock (NQ: HOTH - The Chronicle-Journal
Hoth Therapeutics Is A High-Risk Biotech Betting On Trial Milestones - Finimize
Hoth Therapeutics (HOTH) Stock Volume Volatility (Bearish Momentum) 2026-04-18Trading Community - Cổng thông tin điện tử Tỉnh Sơn La
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Hoth Therapeutics Files 8-K with SEC Detailing Legal Opinion for NASDAQ-Listed Common Stock (HOTH) - Minichart
Hoth Therapeutics Resumes At-the-Market Equity Offering Program - TipRanks
Hoth Therapeutics to resume at-the-market offering with new prospectus filing - Investing.com
Hoth Therapeutics to file new prospectus supplement to resume at-the-market sales - TradingView
Hoth Therapeutics (NASDAQ: HOTH) to restart at-the-market stock program - Stock Titan
Hoth Therapeutics (NASDAQ: HOTH) files ATM prospectus to raise up to $1.56M - Stock Titan
Hoth Therapeutics Reports Positive HT VA Study Data Highlighting GDNF Driven Metabolic Reprogramming In Fatty Liver Disease - BioPharma APAC
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Emerging Now: ANY, GPRO, HOTH, SNAL Shift Strategic Focus in 2026 - openPR.com
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Move Over Novo NordiskThis Small Company Study Flags Edge In Fatty Liver Drug - Benzinga
Positive Results for Hoth Therapeutics (HOTH) in Liver Disease S - GuruFocus
12 Health Care Stocks Moving In Tuesday's Pre-Market SessionAvanos Medical (NYSE:AVNS), Boundless Bio - Benzinga
Hoth reports preclinical data on GDNF for fatty liver disease By Investing.com - Investing.com South Africa
Hoth Therapeutics Inc Stock (HOTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):